Developer docs
API playgroundTry for free, no card

Search company profiles

Bionsight

Full company profile

uuid00033cn

Namestring
Bionsight
Legal namestring
Bionsight, Inc.
Websiteurl
bionsight.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Bionsight is a South Korea-based drug discovery company, founded in 2019 and headquartered in Chuncheon with an additional office in Seoul, that combines proprietary chemoproteomics methodologies with artificial intelligence to accelerate therapeutic target identification and validation. Its core technology stack centers on the Javelin platform, which pairs a novel "massive trypsinization" sample-preparation method with AI-based quantification to deliver proteome-wide peptide- and domain-level protein-ligand interaction maps, including dose-responses, on a 4-6 week timeline. Supporting AI capabilities include Glance for bio-object relationship analysis, Skeleton for 3D structure-based deep learning molecular optimization, and SynapSpec, a DIA mass spectrometry analysis solution with deep learning-optimized workflows; a DI-PELSA thermal shift assay and an internal drug pipeline (BIMM-1, 6, 8, 9, 10 spanning autoimmune, anti-cancer, and metabolic disease) round out the portfolio.

The company monetizes through a three-pronged model: an enterprise target profiling service sold via direct field sales with a consultation-first approach to pharmaceutical and biotech clients, platform technology licensing of its AI and proteomics tools, and internal drug candidate development. Its GTM is sales-led and event-driven, anchored by participation in major proteomics and life sciences conferences (HUPO, ASMS, BIO USA), peer-reviewed publication output, and selection for high-credibility programs including the Merck Research Grants (finalist 2022), Takeda's COCKPI-T funding program (2023), and South Korea's Scale-up TIPS (2024). Customer segments are horizontally distributed across pharmaceutical companies and biotech firms, with no named customer logos publicly disclosed.

Bionsight has raised approximately 55 billion KRW (~$41M USD) in Series A funding (August 2023) from SV Investment, DSC Investment, and Schmidt, supplemented by government Scale-up TIPS grants and prior pre-seed capital, and operates with a 11-50 person team. The company remains privately held with no disclosed revenue, and is positioning itself as a differentiated chemoproteomics-plus-AI alternative to conventional target deconvolution and validation workflows in drug discovery.

Short descriptiontext

Bionsight is a South Korea-based drug discovery company combining proprietary chemoproteomics with AI to deliver proteome-wide target identification and validation services to pharmaceutical and biotech clients on a 4-6 week timeline.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSeoul, South Korea
HQ citystring
Seoul
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI drug discovery, chemoproteomics platform, target identification, mass spectrometry analysis, proteomics services
Industry4 codes
PRIMARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGADAG
Proteomics & Biomarker Analytical Testing
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
  • Analytical Laboratory Instrument Manufacturing334516
SIC code3 codes
  • Services-Commercial Physical & Biological Research8731
  • Laboratory Analytical Instruments3826
  • Pharmaceutical Preparations2834
Product category
AI Drug Discovery Platform
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Target Profiling Service
TypeProfessional Services
Description

End-to-end target profiling service offering AI-powered protein target identification from hypothesis to validation in weeks. Includes target discovery, interaction mapping, data analytics, target validation, safety profiling, and expert support.

bionsight.com
2Platform Technology Licensing
TypeLicensing Royalties
Description

Licensing of AI platform technologies (Javelin, Glance, Skeleton) to pharmaceutical companies and biotech firms for drug discovery applications.

bionsight.com
3Drug Pipeline Development
TypeManaged Services
Description

Internal drug candidate development across autoimmune disease, anti-cancer, and metabolic disease therapeutic areas. Programs include BIMM-1, BIMM-6, BIMM-8, BIMM-9, and BIMM-10 in various stages from discovery to preclinical.

bionsight.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 3 records shown
1Javelin
Description

AI-Assisted Chemoproteomics Platform for protein target exploration, providing proteome-wide peptide/domain-level interaction maps with drug dose-responses in 4-6 weeks.

bionsight.com
+2 more records
Core offering1 text field

Bionsight develops AI-powered chemoproteomics platforms for drug discovery, combining mass spectrometry with machine learning to deliver proteome-wide protein target profiling and validation. Its core offerings include the Javelin chemoproteomics platform, SynapSpec DIA mass spectrometry analysis, and end-to-end Target Profiling Services that identify therapeutic targets, map protein-ligand interactions, and profile off-target effects within 4-6 weeks, replacing multi-year traditional discovery workflows.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 4-6 weeks delivery vs traditional multi-year target identification timelines
+2 more records
Product overview1 text field

Bionsight offers an integrated AI-powered chemoproteomics platform for drug discovery consisting of three core products: Javelin (AI-assisted chemoproteomics platform for proteome-wide target profiling), SynapSpec (advanced DIA mass spectrometry analysis with deep learning optimization), and a Drug Pipeline (therapeutic candidates in autoimmune, anti-cancer, and metabolic disease). The platform is complemented by a Target Profiling Service offering end-to-end外包服务 and the DI-PELSA assay methodology for thermal shift analysis. The company also developed supporting AI technologies including Glance (bio-object relationship analysis) and Skeleton (3D structure-based deep learning for molecular optimization).

Product and service5 records
1Javelin
CategoryAI Chemoproteomics Platform
Description

AI-Assisted Chemoproteomics Platform that delivers proteome-wide peptide/domain-level interaction maps with drug dose-responses in 4-6 weeks. Provides on-target confirmation, binding-site clues at peptide/domain resolution, and off-target lists for go/no-go decisions. Modality-agnostic (small molecules, degraders, ADCs, biologics) and matrix-flexible (cells, organoids, tissues). Designed for pharmaceutical and biotech discovery teams.

2SynapSpec
CategoryProteomics Mass Spectrometry Software
Description

Advanced DIA (Data-Independent Acquisition) Mass Spectrometry Analysis Solution for proteomics, featuring deep learning-optimized workflows, real-time data processing and analysis, automated mass spectrometry optimization, and cross-platform compatibility. Used by pharma and biotech researchers for proteomics analysis supporting drug discovery.

3Drug Pipeline
CategoryTherapeutic Pipeline Development
Description

Therapeutic Development Portfolio encompassing drug candidates across autoimmune disease (BIMM-1, BIMM-8, BIMM-9), anti-cancer (BIMM-10), and metabolic disease (BIMM-6). Programs span discovery to preclinical stages and are pursued for licensing and partnering with global pharmaceutical companies.

4Target Profiling Service
CategoryDiscovery Research Services
Description

End-to-end target profiling service powered by AI and chemoproteomics, offering target discovery, interaction mapping, data analytics, target validation, safety profiling, and expert scientific support. Delivers results in approximately 4 weeks. Targets pharmaceutical companies and biotech firms needing outsourced, comprehensive proteome-wide profiling.

5DI-PELSA
CategoryChemoproteomics Assay Platform
Description

Data-Independent-Precipitation-based Enzyme-Linked Thermal Shift Assay platform used for target profiling of drug candidates in cellular systems. Demonstrated in case studies including MEK1/2 inhibitor profiling in A549 lung cancer cells. Underpins Bionsight's Target Profiling Service and chemoproteomics platform.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeOthersAnnounced on2024-09-05
Description

Selected for Scale-up TIPS program receiving up to 11.4 billion KRW over 3 years for Javelin platform development. Also selected for Post-TIPS 2nd program with 300 million KRW government support. Funds designated for platform technology development, professional hiring, and facilities expansion.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-02-08
Description

Selected for Takeda's COCKPI-T Funding Program - a global initiative to accelerate drug discovery innovation. Provides one year of research support, access to Takeda's research network, joint project execution opportunities, and funding support. Marks an important step in strengthening collaborative R&D capabilities.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Schrödinger operates a physics-based computational platform for molecular design and predicts drug properties using AI/ML, offering comparable target identification and lead optimization services to pharma with similar service-plus-pipeline business model.

TypeDirect peer
Description

Recursion combines high-throughput biology with AI/ML to discover and develop drugs across multiple therapeutic areas, competing with Bionsight in the AI-enabled target identification and pipeline development space.

TypeDirect peer
Description

Exscientia is an AI-driven precision medicine company with a platform that automates drug design and patient stratification, directly comparable to Bionsight's AI-platform-plus-pipeline approach serving pharma clients.

TypeDirect peer
Description

Insitro applies machine learning to disease biology, combining induced pluripotent stem cell models with ML for target discovery and drug development, paralleling Bionsight's AI-biology integration for therapeutic development.

TypeDirect peer
Description

Standigm is a South Korea-based AI drug discovery company that builds proprietary pipelines and offers drug discovery services using AI workflows, the closest regional and stage-comparable peer to Bionsight.

TypeDirect peer
Description

BenevolentAI uses AI to mine biomedical knowledge for target discovery and drug development, offering comparable AI-driven target identification capabilities with a pipeline-plus-services model to pharma.

TypeEmerging player
Description

Atomwise leverages structure-based AI for small molecule drug discovery, sharing Bionsight's AI-driven target-and-lead optimization focus but with greater emphasis on virtual screening rather than chemoproteomics.

TypeEmerging player
Description

Seer provides a proteomics platform (Proteograph) using nanoparticle-enabled mass spectrometry for deep proteomic profiling, comparable to Bionsight's mass spec-driven Javelin target profiling workflow.

TypeEmerging player
Description

Owkin applies AI to multimodal patient data for drug discovery and diagnostics, an adjacent peer sharing AI-biology integration but focused more on patient-derived data than wet-lab chemoproteomics.

TypeBroad incumbent
Description

Bruker is a major mass spectrometry and proteomics instrumentation company whose timsTOF and DIA platforms underpin similar proteomics workflows to Bionsight's SynapSpec, representing a potential partner or competitor in proteomics-grade analytics.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability7 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Bionsight

AI Drug Discovery Platformbionsight.com

Bionsight is a South Korea-based drug discovery company combining proprietary chemoproteomics with AI to deliver proteome-wide target identification and validation services to pharmaceutical and biotech clients on a 4-6 week timeline.

What Bionsight does

Bionsight is a South Korea-based drug discovery company, founded in 2019 and headquartered in Chuncheon with an additional office in Seoul, that combines proprietary chemoproteomics methodologies with artificial intelligence to accelerate therapeutic target identification and validation. Its core technology stack centers on the Javelin platform, which pairs a novel "massive trypsinization" sample-preparation method with AI-based quantification to deliver proteome-wide peptide- and domain-level protein-ligand interaction maps, including dose-responses, on a 4-6 week timeline. Supporting AI capabilities include Glance for bio-object relationship analysis, Skeleton for 3D structure-based deep learning molecular optimization, and SynapSpec, a DIA mass spectrometry analysis solution with deep learning-optimized workflows; a DI-PELSA thermal shift assay and an internal drug pipeline (BIMM-1, 6, 8, 9, 10 spanning autoimmune, anti-cancer, and metabolic disease) round out the portfolio.

The company monetizes through a three-pronged model: an enterprise target profiling service sold via direct field sales with a consultation-first approach to pharmaceutical and biotech clients, platform technology licensing of its AI and proteomics tools, and internal drug candidate development. Its GTM is sales-led and event-driven, anchored by participation in major proteomics and life sciences conferences (HUPO, ASMS, BIO USA), peer-reviewed publication output, and selection for high-credibility programs including the Merck Research Grants (finalist 2022), Takeda's COCKPI-T funding program (2023), and South Korea's Scale-up TIPS (2024). Customer segments are horizontally distributed across pharmaceutical companies and biotech firms, with no named customer logos publicly disclosed.

Bionsight has raised approximately 55 billion KRW (~$41M USD) in Series A funding (August 2023) from SV Investment, DSC Investment, and Schmidt, supplemented by government Scale-up TIPS grants and prior pre-seed capital, and operates with a 11-50 person team. The company remains privately held with no disclosed revenue, and is positioning itself as a differentiated chemoproteomics-plus-AI alternative to conventional target deconvolution and validation workflows in drug discovery.

Bionsight firmographics

Firmographics
Name
Bionsight
Legal name
Bionsight, Inc.
Website
https://bionsight.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
11–50 employees
Short description
Bionsight is a South Korea-based drug discovery company combining proprietary chemoproteomics with AI to deliver proteome-wide target identification and validation services to pharmaceutical and biotech clients on a 4-6 week timeline.
Ownership category
akta.pro rank

Bionsight industry classification

Industry
Product category
AI Drug Discovery Platform
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Analytical Laboratory Instrument Manufacturing (334516)
SIC
Services-Commercial Physical & Biological Research (8731), Laboratory Analytical Instruments (3826), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGADAG
Proteomics & Biomarker Analytical Testing
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • AI drug discovery
  • Chemoproteomics platform
  • Target identification
  • Mass spectrometry analysis
  • Proteomics services

Where Bionsight is headquartered

Location

Headquarters

HQ city
Seoul
HQ country
South Korea
HQ region
Asia

Offices2 records

Markets served

Bionsight business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Target Profiling Service: End-to-end target profiling service offering AI-powered protein target identification from hypothesis to validation in weeks. Includes target discovery, interaction mapping, data analytics, target validation, safety profiling, and expert support.
  2. Platform Technology Licensing: Licensing of AI platform technologies (Javelin, Glance, Skeleton) to pharmaceutical companies and biotech firms for drug discovery applications.
  3. Drug Pipeline Development: Internal drug candidate development across autoimmune disease, anti-cancer, and metabolic disease therapeutic areas. Programs include BIMM-1, BIMM-6, BIMM-8, BIMM-9, and BIMM-10 in various stages from discovery to preclinical.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Bionsight product offering

Product offering

Core offering

Bionsight develops AI-powered chemoproteomics platforms for drug discovery, combining mass spectrometry with machine learning to deliver proteome-wide protein target profiling and validation. Its core offerings include the Javelin chemoproteomics platform, SynapSpec DIA mass spectrometry analysis, and end-to-end Target Profiling Services that identify therapeutic targets, map protein-ligand interactions, and profile off-target effects within 4-6 weeks, replacing multi-year traditional discovery workflows.

Product overview

Bionsight offers an integrated AI-powered chemoproteomics platform for drug discovery consisting of three core products: Javelin (AI-assisted chemoproteomics platform for proteome-wide target profiling), SynapSpec (advanced DIA mass spectrometry analysis with deep learning optimization), and a Drug Pipeline (therapeutic candidates in autoimmune, anti-cancer, and metabolic disease). The platform is complemented by a Target Profiling Service offering end-to-end外包服务 and the DI-PELSA assay methodology for thermal shift analysis. The company also developed supporting AI technologies including Glance (bio-object relationship analysis) and Skeleton (3D structure-based deep learning for molecular optimization).

Differentiator

Problem solved

Functional benefit

Brands

  • Javelin: AI-Assisted Chemoproteomics Platform for protein target exploration, providing proteome-wide peptide/domain-level interaction maps with drug dose-responses in 4-6 weeks.
  • SynapSpec
  • DI-PELSA

Products and services

  • Javelin AI-Assisted Chemoproteomics Platform that delivers proteome-wide peptide/domain-level interaction maps with drug dose-responses in 4-6 weeks. Provides on-target confirmation, binding-site clues at peptide/domain resolution, and off-target lists for go/no-go decisions. Modality-agnostic (small molecules, degraders, ADCs, biologics) and matrix-flexible (cells, organoids, tissues). Designed for pharmaceutical and biotech discovery teams.
  • SynapSpec Advanced DIA (Data-Independent Acquisition) Mass Spectrometry Analysis Solution for proteomics, featuring deep learning-optimized workflows, real-time data processing and analysis, automated mass spectrometry optimization, and cross-platform compatibility. Used by pharma and biotech researchers for proteomics analysis supporting drug discovery.
  • Drug Pipeline Therapeutic Development Portfolio encompassing drug candidates across autoimmune disease (BIMM-1, BIMM-8, BIMM-9), anti-cancer (BIMM-10), and metabolic disease (BIMM-6). Programs span discovery to preclinical stages and are pursued for licensing and partnering with global pharmaceutical companies.
  • Target Profiling Service End-to-end target profiling service powered by AI and chemoproteomics, offering target discovery, interaction mapping, data analytics, target validation, safety profiling, and expert scientific support. Delivers results in approximately 4 weeks. Targets pharmaceutical companies and biotech firms needing outsourced, comprehensive proteome-wide profiling.
  • DI-PELSA Data-Independent-Precipitation-based Enzyme-Linked Thermal Shift Assay platform used for target profiling of drug candidates in cellular systems. Demonstrated in case studies including MEK1/2 inhibitor profiling in A549 lung cancer cells. Underpins Bionsight's Target Profiling Service and chemoproteomics platform.

Quantifiable outcome

  • 4-6 weeks delivery vs traditional multi-year target identification timelines
  • +2 more outcomes

Companies that use Bionsight

Customer profile

Segments2 records

Ideal customer profiles2 records

Bionsight technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature7 records

Bionsight partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Ministry of SMEs and Startups (South Korea)coreOthers · 5 September 2024Selected for Scale-up TIPS program receiving up to 11.4 billion KRW over 3 years for Javelin platform development. Also selected for Post-TIPS 2nd program with 300 million KRW government support. Funds designated for platform technology development, professional hiring, and facilities expansion.
  • Takeda Pharmaceutical Company (COCKPI-T Program)coreStrategic or Co-development Partner · 8 February 2023Selected for Takeda's COCKPI-T Funding Program - a global initiative to accelerate drug discovery innovation. Provides one year of research support, access to Takeda's research network, joint project execution opportunities, and funding support. Marks an important step in strengthening collaborative R&D capabilities.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Bionsight competitors and assessment

Company assessment

Direct peers

  • Schrödinger: Schrödinger operates a physics-based computational platform for molecular design and predicts drug properties using AI/ML, offering comparable target identification and lead optimization services to pharma with similar service-plus-pipeline business model.
  • Recursion Pharmaceuticals: Recursion combines high-throughput biology with AI/ML to discover and develop drugs across multiple therapeutic areas, competing with Bionsight in the AI-enabled target identification and pipeline development space.
  • Exscientia: Exscientia is an AI-driven precision medicine company with a platform that automates drug design and patient stratification, directly comparable to Bionsight's AI-platform-plus-pipeline approach serving pharma clients.
  • Insitro: Insitro applies machine learning to disease biology, combining induced pluripotent stem cell models with ML for target discovery and drug development, paralleling Bionsight's AI-biology integration for therapeutic development.
  • Standigm: Standigm is a South Korea-based AI drug discovery company that builds proprietary pipelines and offers drug discovery services using AI workflows, the closest regional and stage-comparable peer to Bionsight.
  • BenevolentAI: BenevolentAI uses AI to mine biomedical knowledge for target discovery and drug development, offering comparable AI-driven target identification capabilities with a pipeline-plus-services model to pharma.

Emerging players

  • Atomwise: Atomwise leverages structure-based AI for small molecule drug discovery, sharing Bionsight's AI-driven target-and-lead optimization focus but with greater emphasis on virtual screening rather than chemoproteomics.
  • Seer: Seer provides a proteomics platform (Proteograph) using nanoparticle-enabled mass spectrometry for deep proteomic profiling, comparable to Bionsight's mass spec-driven Javelin target profiling workflow.
  • Owkin: Owkin applies AI to multimodal patient data for drug discovery and diagnostics, an adjacent peer sharing AI-biology integration but focused more on patient-derived data than wet-lab chemoproteomics.

Broad incumbents

  • Bruker Corporation: Bruker is a major mass spectrometry and proteomics instrumentation company whose timsTOF and DIA platforms underpin similar proteomics workflows to Bionsight's SynapSpec, representing a potential partner or competitor in proteomics-grade analytics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Bionsight social profiles

Digital presence

Bionsight financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Bionsight leadership team

Management profile

Number of profiles

Profiles3 records

Bionsight funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Bionsight M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bionsight

What does Bionsight do?

Bionsight develops AI-powered chemoproteomics platforms for drug discovery, combining mass spectrometry with machine learning to deliver proteome-wide protein target profiling and validation. Its core offerings include the Javelin chemoproteomics platform, SynapSpec DIA mass spectrometry analysis, and end-to-end Target Profiling Services that identify therapeutic targets, map protein-ligand interactions, and profile off-target effects within 4-6 weeks, replacing multi-year traditional discovery workflows.

Is Bionsight a public or private company?

Bionsight is a private company. It is classified as venture growth investor backed and is currently operating.

When was Bionsight founded?

Bionsight was founded in 2019. It employs 11 to 50 people.

Where is Bionsight based?

Bionsight is headquartered in Seoul, South Korea, in the Asia region.

How does Bionsight make money?

Three revenue lines are on record. Target Profiling Service is the primary driver. The others are platform Technology Licensing and drug Pipeline Development.

Who are Bionsight's main competitors?

Direct peers on record are Schrödinger, Recursion Pharmaceuticals, Exscientia, Insitro, Standigm and BenevolentAI. Emerging players are Atomwise, Seer and Owkin. Bruker Corporation is listed as a broad incumbent.

Does Bionsight have an API?

No public API is recorded for Bionsight.

What industry is Bionsight in?

Bionsight's product category is AI Drug Discovery Platform. Its primary akta.pro industry code is HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation), with a secondary code of HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization. Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals